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Quick summary: This retrospective multi-center study of 27 adrenocortical carcinoma 11 
(ACC) patients evaluated salvage treatment with thalidomide. Best 12 
response was stable disease in two cases. Wide-spread use of 13 
thalidomide as a salvage therapy in ACC is not advisable. 14 
15 
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Abstract 1 
 2 
Objective: Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In advanced 3 
stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary and salvage 4 
treatments are warranted. 5 
Methods: Retrospective cohort study of participants in the prospective European Networks for the 6 
Study of Adrenal Tumours (ENSAT) registry. Main outcome measures were best response during 7 
treatment, progression-free survival (PFS), both measured according to RECIST 1.1 by two blinded 8 
radiologists, and overall survival (OS). 9 
Results: Twenty-seven patients (13 males; median age 44.1 years) progressing after mitotane and a 10 
median of 4 further systemic treatments were included. Thalidomide was administered as tolerated with 11 
a starting dose of 50 mg and target dose of 200 mg /d. The median interval between treatment initiation 12 
and first imaging was 10.5 (4.4-17.5) weeks. The best response to treatment was stable disease (SD, 13 
n=2) and progressive disease (n=25), with a median PFS of 11.2 weeks and a median OS of 36.4 weeks. 14 
The first patient with SD discontinued treatment due to mild epistaxis and diarrhea after 22.3 weeks. 15 
The second patient had SD at the second treatment evaluation after 25.2 weeks and continued 16 
thalidomide but then had clinical progression and deceased after 54.3 weeks. In general, thalidomide 17 
induced only mild or moderate adverse effects (mainly fatigue and gastrointestinal complaints).  18 
Conclusion: Thalidomide was overall well tolerated but resulted in disease control in only 2/27 (7.4%) 19 
patients. In the absence of predictive response markers, thalidomide should only be considered in 20 
exceptional cases as a salvage therapy in ACC. 21 
22 
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Introduction 1 
 2 
Adrenocortical carcinoma (ACC) is an orphan malignancy with a dismal prognosis [1-4]. Complete 3 
tumour removal is still the only potentially curative option and is the initial treatment of choice in 4 
localized disease [5-7]. While the role of surgery in advanced disease remains controversial [8-11], the 5 
adrenostatic agent mitotane is regarded as the cornerstone of medical therapy in advanced disease and 6 
in adjuvant treatment of high-grade ACC [12-18]. The first phase III clinical trial in ACC established 7 
mitotane plus combination chemotherapy with etoposide, doxorubicin, and cisplatin as standard of care 8 
for the treatment of advanced cases [19]. Other cytotoxic chemotherapy regimens include 9 
gemcitabine/capecitabine [20,21] and streptozotocin [22]. In tumours refractory to cytotoxic 10 
chemotherapy, however, treatment options are still scarce. Over the last decade, several cytotoxic and 11 
molecular targeted therapies have been evaluated as potential alternatives [23-28] but failed to reach 12 
significant improvement [29]. In the absence of established treatments, thalidomide has attracted some 13 
interest. Historically prescribed as a hypnotic agent, it was soon banned due to its high teratogenic 14 
potential. Extensive research led to recognition of the anti-angiogenic and immunomodulatory 15 
properties of the drug, resulting in its renaissance as an effective therapy for leprosy and multiple 16 
myeloma for which it is approved in combination with melphalan and prednisone [30-33]. An 17 
encouraging case report published in 2005 showed an impressive tumour response in a female patient 18 
with advanced ACC [34]. Another series described a decrease of tumour burden in four of six ACC 19 
patients treated with thalidomide (either alone or in combination with other mitotane or systemic 20 
chemotherapy [35]. This resulted in subsequent use of thalidomide as an off-label treatment in selected 21 
patients suffering from refractory ACC. Unfortunately, however, the success rate of this salvage therapy 22 
has never been investigated. Hence, we hereby aimed at determining the efficacy and tolerability of 23 
thalidomide in patients with refractory ACC who were prospectively enrolled in the European Network 24 
for the Study of Adrenal Tumours (ENSAT) Registry. 25 
 26 
  27 
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Subjects and Methods 1 
Patients 2 
Patients and clinical parameters (e.g. sex, age at initial diagnosis, evidence of hormone excess, size of 3 
the primary tumour, tumour stage according to the ENSAT classification [36], Weiss score [37], Ki67 4 
index [38,39], date of documented irresectability and subsequent therapies, presence and number of 5 
distant metastases, concomitant treatment with mitotane, and detailed follow-up information) were 6 
retrieved from the German ACC Registry and the ENSAT Registry (www.ensat.org/registry). Both 7 
registries had formerly been approved by the ethics committee of the University of Würzburg (approval 8 
numbers 86/03, and 88/11, respectively). To be included into the study, patient had to fulfill the 9 
following criteria at the time of treatment initiation with thalidomide: age ≥18 years, histologically 10 
confirmed ACC, written informed consent, refractory and measurable progressive disease at baseline, 11 
no prior therapy with thalidomide, treatment with thalidomide for at least 30 days. 12 
 13 
Treatment evaluation 14 
In 24 cases (89%), tumour response was radiologically assessed prior to treatment and from the 15 
beginning of treatment until tumour progression, using the Response Evaluation Criteria In Solid 16 
Tumours (RECIST) guideline version 1.1 for interpretation of imaging results [40]. For this, all imaging 17 
studies were individually reviewed in a blinded fashion by two experienced radiologists (A.H., W.S.). 18 
Follow-up imaging after initiation of thalidomide was not performed in three patients with severe tumour 19 
progression; these cases were only clinically evaluated. Adverse drug effects considered to be treatment 20 
related were retrieved from patient records and graded according to the National Cancer Institute 21 
Common Toxicity Criteria (CTC) version 4.0. In uncertain cases, the physician who originally 22 
supervised the treatment was contacted to clarify potential adverse events. Adverse drug effects at least 23 
considered possibly treatment-related are reported in this study. 24 
 25 
Statistical analysis 26 
Progression-free survival was defined as the interval between the beginning of thalidomide treatment 27 
and the date at which progressive disease was documented at imaging, clinically (e.g. treatment 28 
6 
 
discontinuation due to severely impaired general condition or adverse effects), or death of any cause. 1 
Overall survival was calculated as the time between start of thalidomide and death of any cause or last 2 
follow-up. Survival curves were constructed using the Kaplan-Meier method. Continuous variables are 3 
presented as the median and range and Kaplan-Meier curves as the median and 95% confidence interval 4 
unless otherwise stated. Statistical significance was taken as p<0.05. GraphPad Prism 6.0 software 5 
(GraphPad Software Inc., San Diego, USA) was used for statistical calculations. 6 
 7 
Results 8 
 9 
Patient characteristics 10 
At the time of the final analysis (January 2018), 27 patients fulfilling the inclusion criteria were 11 
identified (pertinent data are given in Table 1). Patients were treated with thalidomide between 2005 12 
and 2017 in 4 European centers participating in the ENSAT Registry. At the time of treatment initiation, 13 
all except one patient had undergone surgical resection (with 13 subjects having at least one surgical re-14 
intervention). Systemic pretreatment was mitotane in all 27 patients (100%); 21 patients (78%) had at 15 
least three prior systemic therapies in addition to mitotane (median of 4 further systemic treatments), 16 
while three patients (11%) had declined any cytotoxic chemotherapy and were pretreated only with 17 
mitotane. The median intervals between initiation of thalidomide and the initial diagnosis of ACC or the 18 
first documentation of metastatic disease were 36.0 months (range 6.0 - 98.9 months) and 25.2 months 19 
(range 0.0 to 72.5 months), respectively.  20 
 21 
Tumour response and survival analysis 22 
Patients were initially treated with a median thalidomide dosage of 100 mg/d (range 50 to 200 mg/d), 23 
usually given once daily. Thalidomide was adjusted according to tolerability and toxicity aiming at a 24 
target dosage of 200mg/d. In a single patient, thalidomide was reduced from 200 to 100 mg per day 25 
because of CTC grade II fatigue. Conversely, dosages were increased in 11 patients to a maximum of 26 
400 mg/d in a single patient. One patient refused to increase the dosage > 50mg/d due to the perceived 27 
risk of adverse effects. The median interval between treatment initiation and subsequent staging was 28 
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10.5 weeks (range 4.4 to 17.5 weeks). Best response to treatment was stable disease in two patients, 1 
whereas 25 patients experienced progressive disease already at the time of their first imaging. The 2 
median progression-free survival was 11.2 weeks (range 4.4 to 22.8 weeks, Figure 1). The first patient 3 
with stable disease refused continuation of treatment due to mild epistaxis and diarrhea after 22.3 weeks 4 
and progressed finally after 34.8 weeks. The second patient had stable disease according to RECIST 5 
criteria at the second staging on treatment after 25.2 weeks. This treatment evaluation was performed 6 
by 18-fluorodeoxyglucose positron emission tomography (F-18-FDG-PET-CT) and revealed increased 7 
tracer uptake of one bone lesion that was previously barely detectable. The patient continued treatment 8 
despite clinical suspicion of tumour progression (bone pain) without interim imaging for 41.6 weeks 9 
and died from ACC 54.3 weeks after treatment initiation. Of note, prior thalidomide he had progressed 10 
to 4 different cytotoxic regimens after a duration of 17 (EDP), 13 (gemcitabine/capecitabine), 9 11 
(streptozotocin), and 26 (trofosfamide) weeks. This patient received a thalidomide dose of only 50 mg/d 12 
since he declined a higher dosage. Mitotane had been discontinued before thalidomide. 13 
At the time of evaluation, all patients have deceased and median OS is 36.4 weeks (range 5.1 to 111.1 14 
weeks, Figure 2).  15 
 16 
Treatment related toxicity 17 
Retrospective information about tolerability was available in 25 patients (93%). Relatively mild 18 
treatment related symptoms (i.e., CTC grades I and II) were observed in 14 patients, whereas 4 patients 19 
experienced more severe adverse events (i.e., CTC grade III). For the remaining 7 patients, no treatment-20 
related side-effects were recorded. Details are given in Table 2. 21 
 22 
Description of two remarkable cases 23 
We observed only two cases with disease stabilization. In the first patient, thalidomide was stopped due 24 
to adverse effects (i.e. epistaxis and diarrhea). The second patient had disease stabilization at the second 25 
treatment evaluation and continued treatment without further tumour evaluation until his death in the 26 
42nd week of treatment at a dose of only 50 mg thalidomide. This patient was diagnosed with an ENSAT 27 
stage II ACC 4.3 years before initiation of thalidomide. The primary tumour had a very low Ki67 index 28 
8 
 
of only 2% and a corresponding Weiss score of 4; biochemically, an androgen excess was observed. 1 
Despite these features, advanced disease was diagnosed after one year. Apart from local recurrence, 2 
metastases were present in both lungs, the peritoneum, and bones (with the latter presenting as diffuse 3 
osteolytic metastasis). Of note, extra-osseous tumour lesions were radiologically stable at the first and 4 
second radiologic evaluation of thalidomide. However, there was also increasing FDG-uptake in a bone 5 
lesion which was retrospectively present at the initial staging on therapy. Bone metastases during 6 
continued thalidomide showed clinical progression, resulting in a pathological fracture which required 7 
surgical stabilization. Hence, overall disease course was characterized by uncontrolled bone metastases 8 
and it is uncertain whether stable disease of measurable tumour lesions really reflected a treatment 9 
related effect. 10 
 11 
Discussion 12 
After an initial very promising case report published in 2005 [34], our study is the first evaluating the 13 
efficacy of thalidomide in ACC. In this series of 27 mostly heavily pre-treated patients, we did not 14 
observe clinically significant single-agent activity of this drug. Whereas 25 of 27 patients (93%) 15 
experienced clinically or radiologically unequivocal progressive disease at the time of first staging, two 16 
patients had stable disease lasting for 25 weeks in one patient. 17 
Over the last few years, systemic therapy for adrenocortical carcinoma has been intensively investigated. 18 
In metastatic disease, mitotane alone or in combination with cytotoxic drugs is considered as a first-line 19 
treatment. It has recently been confirmed that objective tumour response can be expected up to 20% of 20 
selected cases [18]. Cytotoxic chemotherapy is currently regarded as the mainstay of treatment and 21 
combination chemotherapy with etoposide, doxorubicin and cisplatin together with mitotane is currently 22 
considered as a standard of care according to the first international randomized phase III trial in ACC 23 
[19]. Although objective response was observed in 23.2%, progression-free survival is still only 5 24 
months. Other regimens such as gemcitabine/capecitabine [20] result in much lower rates of objective 25 
response. Tumour stabilization is seen in ~25% of patients [21], which is similar to the response obtained 26 
with streptozotocin [19]. Hence, most patients treated with current chemotherapeutic regimes suffer 27 
from insufficiently controlled disease and seek additional treatment options. 28 
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Extensive neo-angiogenesis as a hallmark of tumour growth has attracted attention also in ACC. Due to 1 
the high expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR2) in ACC 2 
tumour cell lines [41,42], prospective phase II clinical trials have been conducted using the multi-3 
tyrosine kinase inhibitors sunitinib and sorafenib [25,26]. However, results were disappointing and are 4 
partly supposed to be related to accelerated metabolism of tyrosine kinase inhibitors through induction 5 
of cytochrome P450 3A4 by mitotane [43,44]. It has been argued that thalidomide may be a promising 6 
therapeutic alternative for solid tumours since it has both anti-angiogenic and immunomodulatory 7 
properties [30-33]. In 2005, the case of a 40-year-old female ACC patient (who experienced a dramatic 8 
tumour response to thalidomide) was reported [34]. Since then, some centers have used thalidomide as 9 
a salvage treatment in selected patients, but efficacy and tolerability have not been systematically 10 
investigated to date. 11 
The present study assessed the efficacy and tolerability of thalidomide in patients with refractory ACC. 12 
We identified 27 patients who received off-label treatment with thalidomide. Before the latter was 13 
initiated, most of the patients had already been treated with several consecutive therapeutic modalities 14 
(e.g. surgery, mitotane, cytotoxic chemotherapy, and radiation therapy).  15 
All remaining patients exhibited progressive disease already at the first staging. A possible explanation 16 
for this disappointing results in these patients may be secondary drug resistance acquired during previous 17 
therapies. However, administering another salvage therapy after various pretreatments is a common 18 
circumstance in patients with refractory ACC. In contrast to many targeted therapies [44], thalidomide 19 
is not metabolized and hence reduced drug exposure through mitotane-induced cytochrome P450 is 20 
unlikely [45], although drug interaction cannot be finally excluded. Overall, thalidomide treatment was 21 
well tolerated but one patient with stable disease declined further treatment after 22.3 weeks due to 22 
relatively mild epistaxis and diarrhea (both CTC grade I). 23 
An obvious limitation of our current evaluation is its retrospective design. This brings along variable 24 
clinical management including restaging at variable time intervals which hampers comparison of 25 
treatment effects. Furthermore, the number of cases in our series is still rather small. However, with 27 26 
patients we would expect an initial signal indicating efficacy if present in a clinically relevant proportion 27 
10 
 
of patients and this number is similar to those in phase II clinical trials of ACC (e.g. [26,46]). Moreover, 1 
it has to be kept in mind that larger series are difficult to collect due to the rarity of ACC. Another 2 
relevant bias of the study is selection bias. As thalidomide was usually offered only as salvage therapy 3 
after failing several other treatment option, this patient cohort is not representative for all patients with 4 
ACC. On one hand, the pre-treatment might have induced - as discussed above - drug resistance, on the 5 
other hand, patients, who are still alive after failing these many treatment regimens, have obviously not 6 
the most aggressive type of ACC. Stable disease as best response in 2 out of 27 patients (7%) may reflect 7 
the natural course of disease.   8 
Absence of response to tyrosine kinase inhibitors in ACC has been previously associated with reduced 9 
drug exposure due to strong induction of drug metabolizing cytochrome P450 enzymes by mitotane 10 
[43,44]. Although we did not measure thalidomide plasma concentrations, only minimal hepatic 11 
metabolism of this drug has been described which renders this possibility rather unlikely. A single 12 
published phase I clinical trials combining lenalidomide - a related immune modulatory drug (IMiD) - 13 
with the mTOR (mammalian target of rapamycin) inhibitor temsirolimus [47] also included three ACC 14 
patients of whom one experienced prolonged disease stabilization. It is unclear whether this effect was 15 
due to lenalidomide or temsirolimus since a phase II trial of temsirolimus with the IGF1-receptor 16 
antibody cixutumuab demonstrated stable disease >6months in 11/26 patients. In general, results of 17 
“IMiDs” in solid tumours were largely disappointing. Since thalidomide was overall well tolerated, one 18 
might reason that higher doses of thalidomide may be used in the future. Combination of thalidomide 19 
with metronomic chemotherapy such as temozolomide [48] or 5-fluorouracil prodrugs [49]might be 20 
another option to achieve better tumour response. 21 
In conclusion, our series provide some evidence that thalidomide has only very modest single-agent 22 
activity in patients with refractory advanced ACC. The majority of patients does not benefit from the 23 
drug. Thus, there is little reason to recommend use of thalidomide as a monotherapy in ACC as long as 24 
molecular or clinical response markers are yet to be discovered. 25 
 26 
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Table 1. Clinical characteristics. Abbreviations are: ENSAT, European Network for the Study of 1 
Adrenal Tumours. 2 
Characteristic Number (%) of patients 
or median (range) 
Number of patients 27 
Female Sex  14 (52%) 
Age at initial diagnosis (years)  44.1 (22.7-64.4) 
ENSAT tumour stage at initial diagnosis 
II 
III 
IV 
 
13 (48) 
6 (22) 
8 (30) 
Main endocrine activity at initial diagnosis 
Glucocorticoid excess 
Androgen excess 
Mineralocorticoid excess 
None or not documented 
 
12 (44) 
5 (19) 
1 (4) 
9 (33) 
 Surgical interventions (number) 
Median (range) 
 
1 (0-6) 
Histopathology 
highest Ki67 (n=24) 
<10% 
10-19% 
≥20% 
Weiss score (n=17) 
 
 
8 (33) 
6 (25) 
10 (42) 
6 (4-9) 
Therapy prior to treatment with thalidomide 
Mitotane 
- continued at the time of thalidomide initiation 
- Median plasma level at the time of thalidomide initiation (mg/l, n=13) 
 
Cytotoxic chemotherapy 
- Etoposide, Doxorubicin, Cisplatin 
- Streptozotocin 
- Gemcitabine, Capecitabine 
- Trofosfamide 
- Etoposide, Cisplatin 
- Etoposide, Carboplatin 
- Gemcitabine, Carboplatin 
- Doxorubicin, Paclitaxel 
 
Targeted therapy 
- Linsitinib 
- Sunitinib 
 
Combined cytotoxic and targeted therapy 
- Capecitabine, vevacizumab 
 
Radiotherapy 
Chemoembolization 
Radio frequency ablation 
131I-Iodometomidate 
None 
 
27 (100) 
13 (48%) 
14.5 (3.5 – 17.6) 
 
24 (89) 
22 (81) 
22 (81) 
20 (74) 
13 (48) 
2 (7) 
1 (4) 
1 (4) 
1 (4) 
 
5 (19) 
3 (11) 
2 (7) 
 
1 (4) 
1 (4) 
 
9 (33) 
4 (15) 
3 (11) 
1 (4) 
0 (0) 
Interval between the initial diagnosis and thalidomide initiation (months) 
Median (range) 
 
36.0 (6.0-98.9) 
Interval between the diagnosis of metastasized ACC and thalidomide initiation (months) 
Median (range) 
 
25.2 (0.0-72.4) 
Age at thalidomide initiation (years) 
Median (range) 
 
46.9 (24.2-69.0) 
17 
 
Tumor burden at thalidomide initiation 
Distant metastasis (multiple lesions) 
Combination of local recurrence and multiple metastases 
Unknown 
 
12 
9 
6 
 1 
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Table 2. Treatment emergent adverse events. Abbreviations are: CTC, Common Toxicity Criteria. 1 
CTC category Side-effects (in alphabetical order) CTC Grade 1 – 2 (n) CTC Grade 3 - 4 (n) 
Blood and lymphatic system Anemia 1  
Gastrointestinal 
Constipation 1  
Decreased appetite 1  
Diarrhea 3  
Ileal obstruction  1 
Nausea 1  
General disorders  
Asthenia  5  
Changes of body weight (loss or gain) 2  
Edema (limb or trunk) 2  
Fatigue  11 1 
Pain (any) 4  
Laboratory investigations Increased creatinine   
Nervous system disorders 
Dizziness  1  
Paresthesia  2  
Respiratory, thoracic and mediastinal  
Dyspnea  1  
Epistaxis  1  
Skin and subcutaneous tissue 
Dry skin 1  
Others (worsening of preexisting psoriasis)  1 
Endocrine disorders Cushing's syndrome 1  
Total 38 3 
 2 
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Figure 1. Kaplan-Meier curve of progression-free survival (PFS) after treatment initiation with 1 
thalidomide.  2 
The patient with PID17 discontinued thalidomide after 32 days of treatment because of fatigue. Patient 3 
with PID 3 continued thalidomide without follow up imaging beyond the last imaging 22.8 weeks after 4 
treatment initiation and was therefore censored for PFS at this time point. He died from ACC after 54.3 5 
weeks. 6 
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Figure 2. Kaplan-Meier curve of the overall survival after treatment initiation with thalidomide. 1 
 2 
 3 
